Biocon Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Biocon obtains approval for weight management drug,Liraglutide, in the United States".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon has received approval from the US FDA to market its Liraglutide Injection (18 mg/3 mL prefilled pens, branded gSaxenda®), a generic version of Saxenda used for chronic weight management in obese or overweight adults. The product is a drug-device combination that works as a GLP-1 receptor agonist, the same fast-growing class that includes popular diabetes and obesity treatments. According to IQVIA data (MAT December 2025), the addressable US market for GLP-1 weight-loss drugs was about USD 127 million, though Biocon views GLP-1 therapies overall as a major long-term growth driver. CEO Siddharth Mittal called the approval a 'defining milestone' and said the company plans to commercialize gSaxenda® in the US at the earliest. This is Biocon's entry into the lucrative GLP-1 obesity space in the world's largest pharmaceutical market.
Positive for shareholders — this is Biocon's first US approval in the high-demand GLP-1 obesity segment and could unlock a new revenue stream, though actual sales will depend on launch timing, pricing, and competition from branded and generic rivals. Near-term stock reaction may be modest given the small reported market size figure, but it strengthens the company's growth narrative.